FDA Approves TREXALL — Teva Women's Health LLC

# FDA Approves Teva Women's Health's Oral Methotrexate Sodium Product Teva Women's Health LLC received FDA approval for TREXALL (methotrexate sodium) oral formulation, expanding the company's portfolio in the competitive generic methotrexate market and positioning Teva to capture additional market share in treatments for autoimmune and oncology indications. The approval strengthens Teva's presence in Women's Health while leveraging methotrexate's established demand across rheumatoid arthritis, psoriasis, and cancer therapy applications.